Clinical trialNCT05856760CompletedPhase 2Interventional

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

SponsorTravere Therapeutics, Inc.Enrollment48Immunoglobulin A Nephropathy

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This was a 28-week, open-label, multicenter, single-group Phase 2 exploratory study to determine the safety and effect of sparsentan in participants with IgAN who are at risk of disease progression to kidney failure despite being on both stable RAASi and SGLT2 inhibitor treatment for at least 12 weeks prior to study entry

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Radko Komers, MD, PhD
Travere Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Hong Kong

Travere Investigational Site
Hong Kong, Hong Kong
Travere Investigational Site
Kowloon, Hong Kong
Travere Investigational Site
Shatin, Hong Kong
Travere Investigational Site
Sheung Wan, Hong Kong
Travere Investigational Site
Tsuen Wan, Hong Kong

United States

Travere Investigational Site
Birmingham, Alabama, United States
Travere Investigational Site
Chula Vista, California, United States
Travere Investigational Site
Garden Grove, California, United States
Travere Investigational Site
Glendale, California, United States
Travere Investigational Site
Denver, Colorado, United States
Travere Investigational Site
Boise, Idaho, United States
Travere Investigational Site
Chubbuck, Idaho, United States
Travere Investigational Site
Idaho Falls, Idaho, United States
Travere Investigational Site
Chicago, Illinois, United States
Travere Investigational Site
Evergreen Park, Illinois, United States
Travere Investigational Site
Fort Wayne, Indiana, United States
Travere Investigational Site
Kansas City, Kansas, United States
Travere Investigational Site
Louisville, Kentucky, United States
Travere Investigational Site
Shreveport, Louisiana, United States
Travere Investigational Site
Albuquerque, New Mexico, United States
Travere Investigation Site
Clifton Park, New York, United States
Travere Investigational Site
Fresh Meadows, New York, United States
Travere Investigational Site
New York, New York, United States
Travere Investigational Site
Jacksonville, North Carolina, United States
Travere Investigational Site
New Bern, North Carolina, United States
Travere Investigational Site
Columbus, Ohio, United States
Travere Investigational Site
Philadelphia, Pennsylvania, United States
Travere Investigational Site
Columbia, South Carolina, United States
Travere Investigational Site
Dallas, Texas, United States
Travere Investigational Site
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sparsentan

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 May 2023
Primary completion: 14 Oct 2024
Completion: 25 Oct 2024
Last update posted: 20 Nov 2025
Registered enrollment: 48
Registry id: NCT05856760

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.